The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Johannes V. Van Thienen
Travel, Accommodations, Expenses - Roche
 
Mariette Schrier
No Relationships to Disclose
 
Kees Hendricksen
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Verastem
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)